An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD

San Diego Sexual Medicine

Status and phase

Not yet enrolling

Phase 2

Conditions

Hypoactive Sexual Desire Disorder

Treatments

Drug: Oral Testosterone Undecanoate

Study type

Interventional

Funder types

Other

Identifiers

NCT06082817

SDSM-2023-03

Details and patient eligibility

About

This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Eligible subjects will receive 50 mg capsules of Kyzatrax® to be taken orally daily over a 3-month period. Multiple blood samples will be taken at baseline and on days 7, 28 and 56 to assess safety and pharmacokinetics of the testosterone. After the informed consent is signed and for up to 14 days after the last dose of study drug, participants will have serial blood samples collected in addition to other routine study procedures (e.g. vital signs measured, adverse events assessed, validated outcome scales completed).

Full description

This study is being conducted in an unblinded fashion because the primary endpoint is pharmacokinetic information, and all subjects will receive the same active drug at the same dosage. The primary objectives of this study are to assess the short-term safety and to investigate the pharmacokinetics of serum concentration of total testosterone with daily administration of one (1) 50 mg capsule of testosterone undecanoate (Kyzatrax®) in thirty menopausal women with hypoactive sexual desire disorder (HSDD) and low testosterone. The secondary objective of this study is to assess the efficacy of daily oral administration of one (1) 50 mg capsule of testosterone undecanoate (Kyzatrax®) in thirty menopausal women with HSDD and low testosterone.

The eligibility criterion for testosterone concentration (< 25 ng/mL [< 0.87 nmol/L]) is based on the lower limit of the normal testosterone reference range for adult females. The dose of 50 mg was chosen because this is the lowest oral testosterone currently being manufactured and it represents 12.5% of the starting dose of Kyzatrex FDA approved for men (see Attachment 1). Based on the guidelines of the International Society for the Study of Women's Sexual Health, the starting dose of testosterone for peri- and post-menopausal women is approximately 10% of a testosterone product FDA approved for men. In clinical practice, women are typically prescribed testosterone therapy at 10-20% of the dose given to men, depending on individual adsorption and metabolism characteristics.

Enrollment

30 estimated patients

Sex

Female

Ages

21 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Participant provides written informed consent and HIPAA authorization before any study procedures are conducted;
Participant is female;
Participant is aged 30 years or greater;
Participant is menopausal either spontaneously (at least 12 months amenorrheic or 6 months amenorrheic and FSH >40 IU/ml) or 6 weeks after bilateral salpingo-oophorectomy with or without hysterectomy.
Participant has a body mass index (BMI) ≤ 34 kg/m2;
Participant has a diagnosis of hypoactive sexual desire disorder;
At screening, participant has a testosterone concentration <30 ng/dL;
Participant has a normal PAP smear within 6 months of first administration of study drug if participant has a cervix;
Participant has a normal mammogram within 6 months of first administration of study drug;
Participant agrees to comply with the study procedures and visits.

Exclusion criteria

Participant has a hypersensitivity to testosterone, gelatin, glycerin, sorbitol, or titanium dioxide (the constituents of Kyzatrex capsule);
Participant has received intramuscular testosterone injections, oral or transdermal testosterone within 4 weeks, or subcutaneous testosterone pellet within 6 months prior to the screening visit, or receives any form of testosterone other than study drug during this trial;
Participant has documented or suspected breast cancer, history of heart attack or stroke;
Participant has a clinically significant history of disease which could alter absorption, distribution, metabolism, or elimination, such as hepatic, renal, hematologic, gastrointestinal, respiratory, endocrine, or neurological disease;
Participant has an EKG with an abnormality of clinical significance;
Participant has an abnormal PAP smear if she has a cervix;
Participant has any chronic medical condition or psychologic disorder that the Principal Investigator feels makes her ineligible for the study;
Participant requires major surgery within 4 weeks before signing consent or at any time during the study;
Participant requires a treatment with any medication listed in Appendix 1 at any time between 30 days before study drug is started or any time until the end of the study;
Participant has a history of substance abuse within 12 months prior to signing consent;
Participant has received an investigational drug within 30 days prior to signing consent;
Participant has any condition or exhibits behavior that indicates to the Principal Investigator that the participant is unlikely to be compliant with study procedures and visits.